Anthrax cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
(7 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
==Overview== | {{Anthrax}} | ||
{{CMG}} | |||
==Overview== | |||
Given the [[morbidity]] and [[mortality]] associated with Anthrax infection, and the low cost of safe and effective [[antibiotics]], current [[pharmacotherapy]] to treat anthrax is relatively cost-effective. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Disease]] | |||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category:Biological weapons]] | [[Category:Biological weapons]] | ||
[[Category:Livestock]] | [[Category:Livestock]] | ||
[[Category:Zoonoses]] | [[Category:Zoonoses]] | ||
[[Category:Medical disasters]] | [[Category:Medical disasters]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category: | [[Category:Dermatology]] | ||
[[Category:Pulmonology]] | |||
[[ | [[Category:Gastroenterology]] | ||
Latest revision as of 20:25, 29 July 2020
Anthrax Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Anthrax cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Anthrax cost-effectiveness of therapy |
Risk calculators and risk factors for Anthrax cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Given the morbidity and mortality associated with Anthrax infection, and the low cost of safe and effective antibiotics, current pharmacotherapy to treat anthrax is relatively cost-effective.